Literature DB >> 28165652

Candidate susceptibility variants for esophageal squamous cell carcinoma.

Iikki Donner1,2, Riku Katainen1,2, Tomas Tanskanen1,2, Eevi Kaasinen1,2, Mervi Aavikko1,2, Kristian Ovaska2, Miia Artama3, Eero Pukkala3, Lauri A Aaltonen1,2.   

Abstract

Esophageal cancer is common worldwide, and often fatal. The major histological subtype is esophageal squamous cell carcinoma (ESCC). ESCC shows familial aggregation and high heritability. Mutations in RHBDF2 cause tylosis, a very rare disorder characterized by high life-time risk of ESCC, but no other well-established predisposition genes have been identified. To identify candidate susceptibility variants for ESCC we utilized the Population Information System and the Finnish cancer registry to find study materials by clustering ESCC patients by family name at birth and municipality at birth. We collected archival tissue material and exome sequenced a total of 30 ESCC cases. We prioritized shared, deleterious and rare variants that were significantly enriched in our sample set compared to Finnish and population subset specific controls. Six variants passed filtering, the most frequent being a nonsense mutation in DNAH9 (p.Tyr1573Ter) found in four unrelated patients. DNAH9 has been reported to be frequently lost in ESCC tumors. In this study, one patient's tumor showed loss of the wild type allele of DNAH9 suggesting a tumor suppressive function. A missense variant in GKAP1 was shared by three patients, and missense variants in BAG1, NFX1, FUK, and DDOST by two each. EP300 which has previously been implicated in the genesis of ESCC had a missense variant segregating in three affected individuals in a single family. If validated in independent patient sets, these variants could serve as a tool towards prevention and early diagnosis of ESCC.
© 2017 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28165652     DOI: 10.1002/gcc.22448

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  4 in total

1.  Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML.

Authors:  Fei Yang; Nicola Long; Tauangtham Anekpuritanang; Daniel Bottomly; Jonathan C Savage; Tiffany Lee; Jose Solis-Ruiz; Uma Borate; Beth Wilmot; Cristina Tognon; Allison M Bock; Daniel A Pollyea; Saikripa Radhakrishnan; Srinidhi Radhakrishnan; Prapti Patel; Robert H Collins; Srinivas Tantravahi; Michael W Deininger; Guang Fan; Brian Druker; Ujwal Shinde; Jeffrey W Tyner; Richard D Press; Shannon McWeeney; Anupriya Agarwal
Journal:  Blood       Date:  2022-02-24       Impact factor: 25.476

Review 2.  A Systematic Literature Review of Whole Exome and Genome Sequencing Population Studies of Genetic Susceptibility to Cancer.

Authors:  Alisa M Goldstein; Elizabeth M Gillanders; Melissa Rotunno; Rolando Barajas; Mindy Clyne; Elise Hoover; Naoko I Simonds; Tram Kim Lam; Leah E Mechanic
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-05-28       Impact factor: 4.254

3.  Discovery of a rare GKAP1-NTRK2 fusion in a pediatric low-grade glioma, leading to targeted treatment with TRK-inhibitor larotrectinib.

Authors:  Lily Deland; Simon Keane; Thomas Olsson Bontell; Helene Sjögren; Henrik Fagman; Ingrid Øra; Esther De La Cuesta; Magnus Tisell; Jonas A Nilsson; Katarina Ejeskär; Magnus Sabel; Frida Abel
Journal:  Cancer Biol Ther       Date:  2021-04-05       Impact factor: 4.742

4.  WNT2 activation through proximal germline deletion predisposes to small intestinal neuroendocrine tumors and intestinal adenocarcinomas.

Authors:  Mervi Aavikko; Eevi Kaasinen; Noora Andersson; Nalle Pentinmikko; Päivi Sulo; Iikki Donner; Päivi Pihlajamaa; Anna Kuosmanen; Simona Bramante; Riku Katainen; Lauri J Sipilä; Samantha Martin; Johanna Arola; Olli Carpén; Ilkka Heiskanen; Jukka-Pekka Mecklin; Jussi Taipale; Ari Ristimäki; Kaisa Lehti; Erika Gucciardo; Pekka Katajisto; Camilla Schalin-Jäntti; Pia Vahteristo; Lauri A Aaltonen
Journal:  Hum Mol Genet       Date:  2021-11-30       Impact factor: 6.150

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.